Evaluation of the effectiveness of the procedures of creating autologous stem cell product derived bone marrow fluid for treatment of ischemic stroke patients

Abstract

Objective: To implement the process and to evaluate the effectiveness of extracting necessary stem cell components and removing unnecessary cell components. Subject and method: 57 patients (40 male and 17 female patients) with subacute ischemic stroke (7th day - 30th day) including 40 male and 17 female patients. 240ml of bone marrow taken from iliac crests of each patient had diluted in 60ml of heparin solution for anticoagulation. Then, we continued to implement concentration process to reduce the volume in order to remove erythrocytes, granulocyte cells, concentrate process on mononucleus cells (including stem cells). Result: After the process, the components of stem cell package collected after concentrating were as follows: The bone marrow-derived stem cell product had the mean concentration of nucleus cells which was 29.07 ± 18.29G/l, the mean concentration of CD34+ stem cells was 549.79 ± 378.55 cells/pl; the rate of CD34+ in total nuclear cells was 1.87 ± 0.94% and the viable CD34+ rate was 94.65 ± 4.62%. The retain ratio of CD34+ stem cells was 57.64 ± 32.35% equivalent to the mean total number of CD34+ stem cells which was 10.99 ± 7.37 × 106 cells. Removal ratio of granulocyte and erythrocyte was 90.09 ± 10.82% and 99.59 ± 0.23%, respectively. Conclusion: The process of creating autologous bone marrow-derived stem cell product for the treatment of patients with subacute ischemic stroke has been effectively performed in term of collecting useful stem cells and eliminating unnecessary cell components.